Library
Sexual healthLimited humanResearch only

Melanotan II

MT-2 · MT-II

A melanocortin agonist that tans skin and raises libido — with a notably troublesome side-effect profile.

Class

Non-selective melanocortin receptor agonist

Half-life

~1–2 hours (variable)

Evidence

Limited human data

Limited human data

Small open-label studies, case series, or trials in a narrow population. Directionally informative, not conclusive.

Overview

Melanotan II is a synthetic analogue of α-MSH that activates melanocortin receptors broadly — including MC1R (skin pigmentation) and MC4R (sexual function and appetite). It is used primarily to darken skin ('injectable tanning') and secondarily for libido, essentially a less selective cousin of PT-141.

That lack of selectivity is the problem. Activating MC1R produces tanning but also drives new and darkening moles, and there are documented case reports of changes in existing moles and concern about melanoma. The broad melanocortin activity also causes nausea, facial flushing, and spontaneous erections.

It has no approval anywhere and a worse risk profile than the approved, more selective PT-141. It is included here because it is widely sold and used, and people deserve a clear-eyed account of why it warrants real caution, particularly around skin cancer risk.

How it works

  • Non-selectively agonises melanocortin receptors (MC1R, MC3R, MC4R, MC5R).
  • MC1R activation drives melanogenesis (tanning) and mole changes.
  • MC4R activation increases sexual arousal and suppresses appetite.
  • Broad activity produces its wide and unpredictable side-effect spread.

What the research shows

Researched effects

  • Skin darkening with reduced UV exposure needed to tan
  • Increased libido and spontaneous erections
  • Appetite suppression
  • Documented mole darkening and new nevi formation

Limitations & what it won't do

  • Non-selective — causes pigmentation, appetite, and sexual effects together whether wanted or not.
  • Documented concern about melanoma and changes to existing moles.
  • No approval and no controlled safety trials.
  • Product purity is unregulated.

Dosing protocols

These ranges reflect published trials and community protocols. They are reference information, not a prescription. Doses are per injection unless noted.

Community protocol (caution advised)

Loading 250–500 mcg; maintenance 500–1000 mcg
FrequencyLoading: daily. Maintenance: 2–3× weekly
RouteSubcutaneous injection
TimingOften evening; nausea is common at first
CycleLoading phase then maintenance; the tan fades when stopped

Documented for reference. Given the melanoma concern, a full skin/mole check before and during use is strongly advised.

Reconstitution & measuring your dose

Handling

Typical vial sizes
10 mg
Suggested BAC water
2 mL
Storage
Lyophilised powder refrigerated at 2–8 °C, protected from light.
After reconstitution
Reconstituted: approximately 30 days refrigerated.

Why 2 mL? A 10 mg vial in 2 mL yields 5000 mcg/mL — 250 mcg lands on 5 units, 500 mcg on 10 units of a U-100 syringe.

Dose calculator

Draw to

5units

= 0.05 mL · 50 mcg per unit

0u100u

Concentration

5000 mcg/mL

Doses per vial

40

Side effects

Common

  • Nausea (especially at first)
  • Facial flushing
  • Spontaneous erections
  • Darkening of moles and freckles
  • Appetite suppression
  • Injection-site reactions

Serious / rare

  • Changes to existing moles / concern for melanoma
  • Priapism (painful prolonged erection)
  • Rhabdomyolysis reported rarely
  • Blood pressure changes

Contraindications & interactions

Do not use if you have

  • Melanoma, atypical moles, or high skin-cancer risk

    Melanotan II drives melanocyte activity and mole changes. A history of melanoma, atypical moles, or heavy mole burden is an absolute contraindication.

  • Active cancer or current oncology treatment

    Avoid during active malignancy.

  • Pregnant, breastfeeding, or trying to conceive

    No pregnancy safety data.

Use caution if you have

  • Cardiovascular disease

    Blood pressure changes warrant caution with cardiovascular disease.

  • High blood pressure

    Can affect blood pressure.

Medication interactions

  • avoidNitratesVasoactive effects combined with nitrates are risky.

Don't stack with

  • PT-141 (Bremelanotide)Both melanocortin agonists — additive nausea, pigmentation, and cardiovascular effects.

What to monitor

  • Full skin and mole examination before and periodically during use — the single most important safeguard
  • Blood pressure

References

Research & educational information only — not medical advice.

You must be 18 or older to use this site. The peptides described are presented as research chemicals intended for research purposes only. Most are not approved by the FDA for human use. Dosing ranges reflect what has appeared in the scientific literature or community protocols and are not prescriptions. Nothing here replaces evaluation by a licensed physician who knows your full medical history.

Want to know if Melanotan II fits your goals and history?

The assessment cross-checks your medical history and medications against this and every other compound before it recommends anything.

Start the assessment